ProMIS Neurosciences

PMN · NASDAQ

$8.09−$0.14 (−1.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.23

Latest news

Press releaseOct 6, 7:05 AM ETGlobe Newswire
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
NewsAug 13, 5:24 PM ET
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseAug 13, 4:00 PM ETGlobe Newswire
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
NewsJul 28, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsJul 28, 12:30 PM ETVandana Singh
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
NewsJul 28, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsJul 28, 7:21 AM ET
Market-Moving News for July 28th
Press releaseJul 28, 6:00 AM ETGlobe Newswire
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
NewsJul 28, 5:01 AM ETAvi Kapoor
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
NewsJul 27, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseJul 14, 2:30 AM ETGlobe Newswire
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
Press releaseMay 28, 10:13 AM ETGlobe Newswire
ProMIS Neurosciences to Participate in Upcoming Conferences in June
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseMay 12, 6:30 AM ETGlobe Newswire
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Press releaseMar 25, 8:00 AM ETGlobe Newswire
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Press releaseMar 18, 8:00 AM ETGlobe Newswire
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
NewsMar 16, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsFeb 25, 4:07 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsFeb 3, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsFeb 3, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJan 30, 8:00 AM ETGlobe Newswire
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Press releaseDec 18, 7:30 AM ETGlobe Newswire
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
Press releaseDec 10, 7:30 AM ETGlobe Newswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Press releaseDec 1, 7:30 AM ETGlobe Newswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
NewsNov 24, 12:08 PM ETAvi Kapoor
Dow Jumps 300 Points; Waldencast Shares Plunge
NewsNov 24, 9:47 AM ETAvi Kapoor
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
Press releaseNov 24, 8:00 AM ETGlobe Newswire
ProMIS Neurosciences Announces Reverse Stock Split
NewsNov 19, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 12, 7:00 AM ETGlobe Newswire
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Press releaseOct 22, 7:30 AM ETGlobe Newswire
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Press releaseSep 18, 9:10 AM ETPRNewswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
NewsSep 5, 8:07 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseSep 3, 7:00 AM ETGlobe Newswire
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310
Press releaseAug 13, 7:00 AM ETGlobe Newswire
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
NewsAug 1, 4:52 PM ETChris Katje
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
NewsJul 23, 5:00 AM ETAvi Kapoor
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
NewsJul 21, 12:12 PM ETAvi Kapoor
Nasdaq Surges Over 100 Points; Domino's Shares Fall After Q2 Results
NewsJul 21, 9:50 AM ETAvi Kapoor
Dow Gains 50 Points; Verizon Earnings Top Views
Press releaseJul 21, 8:00 AM ETGlobe Newswire
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease
NewsSep 19, 5:26 AM ETAvi Kapoor
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

12 Health Care Stocks Moving In Tuesday's Intraday Session

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Market-Moving News for July 28th

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Monday's After-Market Session

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Earnings Scheduled For May 12, 2026

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dow Jumps 300 Points; Waldencast Shares Plunge

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

ProMIS Neurosciences Announces Reverse Stock Split

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

12 Health Care Stocks Moving In Friday's Pre-Market Session

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?

Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Nasdaq Surges Over 100 Points; Domino's Shares Fall After Q2 Results

Dow Gains 50 Points; Verizon Earnings Top Views

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket